AIM ImmunoTech Inc AIM
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 1996-07-12 |
| Shares Out. | 27,720,000 |
| Website | aimimmuno.com/ ↗ |
| Phone | 13026365400 |
| Employees | 21 |
| Revenue | $22,000 |
| Gross Profit | $18,000 |
| Net Income | -$3.0M |
| Total Assets | $8.6M |
| Total Liabilities | $6.5M |
| Equity | $2.1M |
About AIM ImmunoTech Inc
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
AIM ImmunoTech Inc is a publicly traded company under the ticker symbol AIM on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-07-01)